文献速递心脏核医学肿瘤 PET/CT

靶向成纤维细胞激活蛋白分子影像评估肺动脉高压纤维化重构

Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension.
PubMed 文献 · J Nucl Med · 2025-01-03

本研究在大鼠 monocrotaline 诱导的肺动脉高压模型中行 18F-FAPI PET/CT 与组织学分析,并纳入 38 例肺动脉高压患者行 18F-FAPI PET/CT,评估肺动脉与右心室纤维化重构的可行性;结果显示 18F-FAPI PET/CT 对可视化肺动脉与右心室重构可行,但其在评估疾病严重程度与监测疗效方面的作用需进一步研究。

要点

  • 大鼠模型中,注射后第 14 天心肌与肺的 18F-FAPI 摄取及成纤维细胞激活蛋白表达达峰值。
  • 38 例肺动脉高压患者中,18F-FAPI PET/CT 识别出心肌及近端与远端肺动脉不同程度的 18F-FAPI 摄取。
  • 5 例随访患者在靶向治疗 6 个月(范围 4–9 个月)后复查,其中 3 例 18F-FAPI 摄取减低并与临床改善相对应。

核心结论

  • 18F-FAPI PET/CT 对可视化肺动脉高压中肺动脉与右心室的重构是可行的。
  • 18F-FAPI PET/CT 虽有望用于评估疾病相关变化,但其在评估疾病严重程度与监测治疗效果方面的作用需进一步研究。

研究设计与样本

  • 在大鼠 monocrotaline 诱导的肺动脉高压模型中,完成 18F-FAPI PET/CT 与血流动力学测量后于不同时间点处死大鼠行组织分析(成纤维细胞激活蛋白免疫荧光与 Masson 三色染色)。
  • 纳入 38 例肺动脉高压患者行 18F-FAPI PET/CT 显像,并在 1 周内行右心导管与超声心动图评估肺血流动力学与心脏功能。

主要发现

  • 动物实验中,monocrotaline 大鼠右心室收缩压从注射后第 14 天至第 21 天升高。
  • 大鼠心肌与肺的 18F-FAPI 摄取及成纤维细胞激活蛋白表达在注射后第 14 天达峰值。
  • monocrotaline 大鼠右心室与外周肺动脉的胶原沉积从第 14 天至第 21 天进行性恶化。
  • 人肺动脉高压研究中,18F-FAPI PET/CT 识别出心肌及近端与远端肺动脉不同程度的 18F-FAPI 摄取,并与临床、右心室功能及肺血流动力学参数相关。
  • 5 例随访患者在肺动脉高压靶向治疗 6 个月(范围 4–9 个月)后行第二次 18F-FAPI PET/CT,其中 3 例 18F-FAPI 摄取减低并与临床改善相对应。

临床怎么用

  • 18F-FAPI PET/CT 显像对可视化肺动脉高压中肺动脉与右心室的重构是可行的。

局限性

  • 18F-FAPI PET/CT 在评估疾病严重程度与监测治疗效果方面的作用需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to investigate the feasibility of using 18F-labeled fibroblast activation protein inhibitor (FAPI) PET/CT in assessing the fibrotic remodeling of the pulmonary artery (PA) and the right ventricle (RV) in pulmonary arterial hypertension (PAH). Methods: In a rat model of monocrotaline-induced PAH, rats were euthanized at different time points for tissue analysis (fibroblast activation protein immunofluorescence and Masson's trichrome staining) after completing 18F-FAPI PET/CT and hemodynamic measurements. Thirty-eight PAH patients were enrolled to participate in 18F-FAPI PET/CT imaging, with right heart catheterization and echocardiography performed within 1 wk to assess pulmonary hemodynamics and cardiac function. Results: In the animal experiments, RV systolic pressure in monocrotaline rats increased from day 14 to day 21 after injection. 18F-FAPI uptake and fibroblast activation protein expression in the myocardium and lungs peaked on day 14 after injection. Collagen deposition in the RVs and peripheral PAs of monocrotaline rats progressively deteriorated from day 14 to day 21. In the human PAH study, 18F-FAPI PET/CT imaging identified varying degrees of 18F-FAPI uptake in the myocardium and proximal and distal PAs, correlating with clinical, RV function, and pulmonary hemodynamic parameters. Among the 5 follow-up patients who underwent a second 18F-FAPI PET/CT scan after 6 mo (range, 4-9 mo) of PAH-targeted therapy, 3 demonstrated reduced 18F-FAPI uptake, corresponding with clinical improvement. Conclusion: 18F-FAPI PET/CT imaging is feasible for visualizing the remodeling of the PA and the RV in PAH. Although it offers promise for assessing disease-related changes, its role in evaluating disease severity and monitoring therapeutic efficacy requires further investigation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hou P, Chen H, Liang S, et al. Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension. J Nucl Med. 2025. PMID: 39753365. doi:10.2967/jnumed.124.268376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。